These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24105030)

  • 1. Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals.
    Wada N; Jacobson LP; Cohen M; French A; Phair J; Muñoz A
    AIDS; 2014 Jan; 28(2):257-65. PubMed ID: 24105030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.
    Writing Committee for the CASCADE Collaboration
    Arch Intern Med; 2011 Sep; 171(17):1560-9. PubMed ID: 21949165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008.
    Wada N; Jacobson LP; Cohen M; French A; Phair J; Muñoz A
    Am J Epidemiol; 2013 Jan; 177(2):116-25. PubMed ID: 23287403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
    ; Cain LE; Logan R; Robins JM; Sterne JA; Sabin C; Bansi L; Justice A; Goulet J; van Sighem A; de Wolf F; Bucher HC; von Wyl V; Esteve A; Casabona J; del Amo J; Moreno S; Seng R; Meyer L; Perez-Hoyos S; Muga R; Lodi S; Lanoy E; Costagliola D; Hernan MA
    Ann Intern Med; 2011 Apr; 154(8):509-15. PubMed ID: 21502648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women.
    Estrella MM; Parekh RS; Abraham A; Astor BC; Szczech LA; Anastos K; Dehovitz JA; Merenstein DJ; Pearce CL; Tien PC; Cohen MH; Gange SJ
    J Acquir Immune Defic Syndr; 2010 Oct; 55(2):217-20. PubMed ID: 20581688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment.
    Palella FJ; Baker RK; Buchacz K; Chmiel JS; Tedaldi EM; Novak RM; Durham MD; Brooks JT;
    AIDS; 2011 Sep; 25(15):1865-76. PubMed ID: 21811144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.
    Anastos K; Barrón Y; Cohen MH; Greenblatt RM; Minkoff H; Levine A; Young M; Gange SJ
    Ann Intern Med; 2004 Feb; 140(4):256-64. PubMed ID: 14970148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients.
    Hoffmann CJ; Seaberg EC; Young S; Witt MD; D'Acunto K; Phair J; Thio CL
    AIDS; 2009 Sep; 23(14):1881-9. PubMed ID: 19550291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
    Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
    Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
    Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
    Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
    Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
    Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.
    Palella FJ; Baker RK; Moorman AC; Chmiel JS; Wood KC; Brooks JT; Holmberg SD;
    J Acquir Immune Defic Syndr; 2006 Sep; 43(1):27-34. PubMed ID: 16878047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early mortality and cause of deaths in patients using HAART in Brazil and the United States.
    Grinsztejn B; Veloso VG; Friedman RK; Moreira RI; Luz PM; Campos DP; Pilotto JH; Cardoso SW; Keruly JC; Moore RD
    AIDS; 2009 Oct; 23(16):2107-14. PubMed ID: 19770698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C and progression of HIV disease.
    Sulkowski MS; Moore RD; Mehta SH; Chaisson RE; Thomas DL
    JAMA; 2002 Jul; 288(2):199-206. PubMed ID: 12095384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of HAART on the respiratory complications of HIV infection: longitudinal trends in the MACS and WIHS cohorts.
    Gingo MR; Balasubramani GK; Kingsley L; Rinaldo CR; Alden CB; Detels R; Greenblatt RM; Hessol NA; Holman S; Huang L; Kleerup EC; Phair J; Sutton SH; Seaberg EC; Margolick JB; Wisniewski SR; Morris A
    PLoS One; 2013; 8(3):e58812. PubMed ID: 23554932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.
    Murray M; Hogg RS; Lima VD; May MT; Moore DM; Abgrall S; Bruyand M; D'Arminio Monforte A; Tural C; Gill MJ; Harris RJ; Reiss P; Justice A; Kirk O; Saag M; Smith CJ; Weber R; Rockstroh J; Khaykin P; Sterne JA;
    HIV Med; 2012 Feb; 13(2):89-97. PubMed ID: 21819529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS.
    Plettenberg A; Brockmeyer NH; Haastert B; Michalik C; Dupke S; Schewe K; Rausch M; Hower M; Ulmer A; Wolf E; Lorenzen T; Arendt G; Jansen K;
    Infection; 2011 Feb; 39(1):3-12. PubMed ID: 21221704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality in members of HIV-1 serodiscordant couples in Africa and implications for antiretroviral therapy initiation: results of analyses from a multicenter randomized trial.
    de Bruyn G; Magaret A; Baeten JM; Lingappa JR; Ndase P; Celum C; Wald A;
    BMC Infect Dis; 2012 Oct; 12():277. PubMed ID: 23130818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men.
    Kaplan RC; Kingsley LA; Gange SJ; Benning L; Jacobson LP; Lazar J; Anastos K; Tien PC; Sharrett AR; Hodis HN
    AIDS; 2008 Aug; 22(13):1615-24. PubMed ID: 18670221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa.
    Kroeze S; Ondoa P; Kityo CM; Siwale M; Akanmu S; Wellington M; de Jager M; Ive P; Mandaliya K; Stevens W; Boender TS; de Pundert ME; Sigaloff KCE; Reiss P; Wit FWNM; Rinke de Wit TF; Hamers RL
    AIDS; 2018 May; 32(8):1043-1051. PubMed ID: 29547445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.